Schlesinger 2020.

Study name	Short‐term outcome of mild to moderate atopic dermatitis using a combination treatment of crisaborole ointment 2% and a concomitant topical cortiscosteroid
Methods	Trial design: randomised study Trial registration number: not reported Country: USA Outpatient or hospital, date trial conducted: not reported Duration of trial participation: 8 weeks Inclusion criteria: · Mild‐to‐moderate AD · Aged 2 to 79 years Exclusion criteria: not reported Additional design details: none
Participants	Total number randomised: 16 Age: 2 to 79 years Sex, ethnicity, duration of eczema: not reported Severity of eczema: mild‐to‐moderate Body site, number of withdrawals: not reported Notes: none
Interventions	Run‐in details: not reported Intervention: crisaborole 2% with triamcinolone acetonide 0.1% ointment used at unspecified frequency for 8 weeks · Concurrent treatment: not reported · Other key information: none Comparator: crisaborole 2.% ointment used at unspecified frequency for 8 weeks · Concurrent treatment: not reported · Other key information: none Concurrent treatments received alongside both intervention and comparator: not reported Notes: none
Outcomes	· Percentage with IGA 0 = clear or 1 = or almost clear with a > 2 grade improvement from baseline · Reduction in ADSI · Improvement in SCORAD · Reduction in pruritus
Starting date	Not reported
Contact information	Not reported
Notes	Funding source: Pfizer Declarations of interest: industry‐funded Original language of publication: English Other: none